Change search
ReferencesLink to record
Permanent link

Direct link
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology. Univ Uppsala Hosp, Dept Oncol, S-75185 Uppsala, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Radiology. Univ Uppsala Hosp, Dept Oncol, S-75185 Uppsala, Sweden..
Novartis Sverige AB, Kemistvagen 1, S-18379 Taby, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology. Univ Uppsala Hosp, Dept Oncol, S-75185 Uppsala, Sweden..
2016 (English)In: BMC Cancer, ISSN 1471-2407, E-ISSN 1471-2407, Vol. 16, 634Article in journal (Refereed) Published
Abstract [en]

Background: Conjunctival malignant melanoma (CMM) is a rare malignancy and in the advanced setting there is no effective treatment. In contrast, half of cutaneous melanomas have BRAF mutations and treatment with BRAF inhibitors is established for patients with disseminated disease. The most common form of ocular melanoma, uveal melanoma, lacks these mutations, however, their presence has been reported for CMM. Case presentation: We used the BRAF inhibitor vemurafenib to treat a 53 year-old female suffering from a BRAFV600E mutated metastatic CMM. The patient benefited from the treatment, a response was evident within a week and she experienced a progression free survival of four months. Conclusions: To our knowledge, this is the first described case of response to vemurafenib treatment in a patient with ocular melanoma.

Place, publisher, year, edition, pages
2016. Vol. 16, 634
Keyword [en]
BRAF inhibitor, BRAF mutation, Conjunctival malignant melanoma, Ocular melanoma, Vemurafenib
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-305937DOI: 10.1186/s12885-016-2657-7ISI: 000384169800001PubMedID: 27520988OAI: oai:DiVA.org:uu-305937DiVA: diva2:1045895
Available from: 2016-11-11 Created: 2016-10-24 Last updated: 2016-11-11Bibliographically approved

Open Access in DiVA

fulltext(907 kB)28 downloads
File information
File name FULLTEXT01.pdfFile size 907 kBChecksum SHA-512
4bdd2489ed1ffd59f961adb26c49f12890203c7823fa5cb4e2bca7860b93e296765badb0aa13c612fd5be4520a7c0e540dab1cd916c37d5ef4a150e0ce975a26
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Maleka, AglaiaÅström, GunnarUllenhag, Gustav J.
By organisation
Experimental and Clinical OncologyRadiology
In the same journal
BMC Cancer
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 28 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 30 hits
ReferencesLink to record
Permanent link

Direct link